Medtronic has received FDA approval for its Percept RC Deep Brain Stimulation (DBS) system, marking a significant milestone in healthcare technology. As part of the Percept family, it is the only sensing-enabled DBS system available, offering personalised treatment for movement disorders such as Parkinson’s disease, essential tremor, dystonia, and epilepsy. The Percept RC, recognised as the smallest and thinnest dual-channel neurostimulator for DBS, incorporates BrainSense technology to capture and record brain signals. This enables healthcare providers to customise therapy based on evolving patient needs.
Utilising surgically implanted devices resembling cardiac pacemakers, Medtronic's Percept neurostimulators use slender wires to transmit electrical signals to specific brain targets affected by neurological disorders. The Percept RC battery, equipped with Medtronic's patented technology, ensures a service life of at least 15 years with consistent and rapid recharge performance. Notably, it allows for fast recharging from 10% to 90% full charge in less than an hour. Medtronic was the first in the U.S. to offer full-body MR Conditional DBS systems, enabling safe scans for patients, which is vital as a significant percentage of DBS-eligible patients may require MRI as part of their essential care.
Amaza Reitmeier, Vice President and General Manager at Medtronic, highlighted the transformative impact of DBS therapy with BrainSense technology, particularly in controlling debilitating tremors for those with Parkinson's. The innovation underscores Medtronic's commitment to advancing brain modulation through sensing-enabled DBS, with a focus on improving the lives of more individuals through therapy innovation.
Click here to read the original news story.